Radiant Research Expands Consumer Product Testing Division
Radiant Research, Inc., a leading provider of clinical and consumer product testing, has expanded its consumer division.
Radiant Research, Inc., a leading provider of clinical and consumer product testing, has expanded its consumer division. This expansion includes additional geographic locations and increased product testing capabilities. The changes give Radiant’s consumer testing sites the ability to conduct studies in more diverse dermatological disease states, as well as in a varied demographical healthy normal population, with new bioinstrumentation resources.
“Radiant has become an industry leader in complex consumer trials since launching this specialized division in 2011,” said Tara Kelley, vice president of operations for Radiant Research. “Now, we’re giving our clients more options for their consumer testing needs by adding new locations and specialty populations. We’ve also made the process more efficient by integrating our consumer product and clinical trial database – giving us access to one million potential study participants.”
As part of its commitment to safe, effective and efficient consumer product testing, Radiant Research staffs clinical coordinators, recruitment specialists, technicians and medical research specialists at each site. Additionally, the sites are supported by a central team of experienced professionals who provide resources that are unmatched in the industry.
In addition to the wide range of claim support studies, Radiant Research has expanded its Dermal Safety testing to include the following: Cumulative Irritation, Phototoxicity, Contact Sensitization, Primary Irritation, Photoallergy and Transdermal Delivery Systems at multiple locations.
Radiant Research encourages those with consumer product testing needs to visithttp://www.radiantresearch.com and contact Charley Folk at 480-699-3406 or [email protected].
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
